publication date: Apr. 14, 2017

Guest Editorial How not to develop a medical intervention: Learning from the prostate screening debacle

By Otis Brawley, MD, MACP

Chief medical officer, American Cancer Society, Inc.

Otis_Brawley

 

This week, the USPSTF issued its draft guidelines for prostate cancer screening. They propose shifting from task force’s recommendation against routine prostate cancer screening to a recommendation for informed and shared decision-making in which the physician and patient discuss the real risks of harm and the potential for life saving benefit before deciding on screening.

This guideline brings the TF in line with the guidelines of the American College of Physicians, the American Cancer Society, and the American Urological Association. It is useful to briefly review how we got here. This is a history of how not to develop a medical intervention. It is a story of ignorance and greed, and panic, and profiles in courage.

PCa is a leading cause of death. Metastatic prostate cancer causes tremendous pain and suffering. These are clear reasons demonstrating a need for an effective screening test and effective treatment. Perhaps the most important word in the last sentence is “effective.”

The serum prostate specific … Continue reading How not to develop a medical intervention: Learning from the prostate screening debacle

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.